Amniotics is advancing its own pipeline and is moving into clinical development with the leading drug candidate, PulmoStem™ targeting anti-inflammatory and anti-fibrotic disease of the lung.

Other drug candidates for diseases in the brain, skin and kidney are in pre-clinical development.

We are actively looking to establish strategic partnerships with researchers and companies around the world to enable and accelerate the development of our stem-cell-based therapies.